13,735 Shares in Gilead Sciences, Inc. $GILD Bought by Empirical Asset Management LLC

Empirical Asset Management LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,735 shares of the biopharmaceutical company’s stock, valued at approximately $1,735,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Great Lakes Advisors LLC purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $7,890,000. Avaii Wealth Management LLC purchased a new stake in shares of Gilead Sciences in the second quarter worth $420,000. Danske Bank A S bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $106,176,000. Diversify Advisory Services LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $1,817,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $378,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 82,000 shares of company stock valued at $10,837,860. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $143.44 on Wednesday. The company has a market cap of $177.86 billion, a P/E ratio of -53.72 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm’s fifty day moving average is $130.69 and its two-hundred day moving average is $136.46.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: A federal appeals court blocked companies from importing and selling cheaper foreign versions of Biktarvy in the United States. The ruling helps protect revenue from Gilead’s leading HIV treatment and removes a potential competitive and pricing threat. Gilead stock court ruling on Biktarvy imports
• Positive Sentiment: Gilead’s HIV franchise remains the primary growth engine. Biktarvy continues to lead treatment, while the newer Yeztugo product and additional pipeline programs could expand the company’s prevention and treatment opportunities. Is Gilead’s Expanding HIV Portfolio a Growth Catalyst?
• Positive Sentiment: Commentary from The Motley Fool highlighted Gilead as an underappreciated healthcare turnaround story, citing double-digit quarterly revenue growth, strong HIV sales, acquisitions, and an expanding oncology portfolio. This supports investor optimism about longer-term diversification beyond HIV. Gilead Sciences turnaround story
• Neutral Sentiment: Gilead is participating in a highly competitive antibody-drug conjugate oncology market. The company’s technology and patent position may create future opportunities, but the landscape also involves substantial competition and development risk. Cancer and antibody-drug conjugates patent landscape
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares worth approximately $3.85 million. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal about management’s outlook, though insider selling can still weigh modestly on sentiment.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Needham & Company LLC restated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Rothschild & Co Redburn dropped their price objective on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.